Summary

FIELD (Fenofibrate Intervention and Event lowering in Diabetes), the largest type 2 diabetes intervention trial, looked at fenofibrate's effects on coronary mortality and morbidity. FIELD lead investigator professor Anthony Keech, MD, University of Sydney, Australia, stated “Atherogenic diabetic dyslipidemia may be particularly amenable to fibrate therapy.” He noted that fenofibrate reduces triglycerides (TG), total cholesterol (TC), and LDL cholesterol while increasing HDL cholesterol.